PDCD1 and cancer: Despite the promising outcomes with anti-PD-1 or anti-PD-L1 antibodies in a variety of cancer, there is a dearth of information on the safety and efficacy of using these drugs in PLWH because these patients are frequently omitted from clinical trials.